Do 5-alpha reductase inhibitors decrease the risk of recurrent gross hematuria in patients who have had a transurethral prostatectomy?

摘要

Benign prostatic enlargement is a common cause of urinary symptoms in aging men. Some men require a transurethral prostatectomy (TURP). Previous research has shown that use of prostate-specific medication is common after TURP, despite having limited physiological basis or evidence to support their use.1 5-alpha reductase inhibitors (5ARIs) are one category of these medications and are used at some point by almost 30% of men in the first 10 years after a TURP.1 In our experience, they are often prescribed for gross hematuria in patients who have had a TURP. Our objective was to determine if 5ARI use after an episode of post-TURP gross hematuria reduces the risk of further episodes of gross hematuria.